Issues and concerns in nanotech product development and its commercialization

Kaur, Indu Pal; Kakkar, Vandita; Deol, Parneet Kaur; Yadav, Monika; Singh, Mandeep; Sharma, Ikksheta

doi:10.1016/j.jconrel.2014.06.005

Cited by 94 publications

(48 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several specific safety issues can affect this process, primarily pertaining to: 1) the set-up and validation of standardized in vitro assays, with suitable reference materials; 2) the development of ex vivo/ in vivo models relevant for the route of administration; 3) the generation of in silico approaches which are predictive for biological and toxicological responses; and 4) in vivo pharmacokinetic studies. 25 Finally, the interactions of NMbased medicines with the major biological systems deserve particular attention from coordinated contributions of multidisciplinary competences. …”

Section: Regulatory Issuesmentioning

confidence: 99%

Nanoparticle–allergen complexes for allergen immunotherapy

Felice¹,

Colombo²

2017

IJN

View full text Add to dashboard Cite

Allergen-specific immunotherapy was introduced in clinical settings more than 100 years ago. It remains the only curative approach to treating allergic disorders that ameliorates symptoms, reduces medication costs, and blocks the onset of new sensitizations. Despite this clinical evidence and knowledge of some immunological mechanisms, there remain some open questions regarding the safety and efficacy of this treatment. This suggests the need for novel therapeutic approaches that attempt to reduce the dose and frequency of treatment administration, improving patient compliance, and reducing costs. In this context, the use of novel adjuvants has been proposed and, in recent years, biomedical applications using nanoparticles have been exploited in the attempt to find formulations with improved stability, bioavailability, favorable biodistribution profiles, and the capability of targeting specific cell populations. In this article, we review some of the most relevant regulatory aspects and challenges concerning nanoparticle-based formulations with immunomodulatory potential, their related immunosafety issues, and the nature of the nanoparticles most widely employed in the allergy field. Furthermore, we report in vitro and in vivo data published using allergen/nanoparticle systems, discuss their impact on the immune system in terms of immunomodulatory activity and the reduction of side effects, and show that this strategy is a novel and promising tool for the development of allergy vaccines.

show abstract

Section: Regulatory Issuesmentioning

confidence: 99%

Nanoparticle–allergen complexes for allergen immunotherapy

Felice¹,

Colombo²

2017

IJN

View full text Add to dashboard Cite

show abstract

“…The National Nanotechnology Initiative and ASTM International have defined nanotechnology as a term that refers to technologies that manufacture and manipulate materials with a dimension between 1 and 100 nm to exploit their novel properties. They are expanding the design, characterization, synthesis, limitations, toxicity, and applications of nanomaterials (Khajeh et al, 2013;Kaur et al, 2014). Further, nanostructure is defined as a specified structural object with development of resistance (Pelgrift and Friedman, 2013;Leid et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Antimicrobial Nanostructures for Neurodegenerative Infections

Muthuraman

Kaur

2017

Nanostructures for Antimicrobial Therapy

View full text Add to dashboard Cite

“…, Doxil, Abraxane, and Genexol) have been approved by the regulatory agencies to treat cancer patients. 10 …”

Section: Introductionmentioning

confidence: 99%

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Snow-Davis

et al. 2016

JoVE

View full text Add to dashboard Cite

Micelles have been successfully used for the delivery of anticancer drugs. Amphiphilic polymers form core-shell structured micelles in an aqueous environment through self-assembly. The hydrophobic core of micelles functions as a drug reservoir and encapsulates hydrophobic drugs. The hydrophilic shell prevents the aggregation of micelles and also prolongs their systemic circulation in vivo. In this protocol, we describe a method to synthesize a doxorubicin lipophilic pro-drug, doxorubicin-palmitic acid (DOX-PA), which will enhance drug loading into micelles. A pH-sensitive hydrazone linker was used to conjugate doxorubicin with the lipid, which facilitates the release of free doxorubicin inside cancer cells. Synthesized DOX-PA was purified with a silica gel column using dichloromethane/methanol as the eluent. Purified DOX-PA was analyzed with thin layer chromatography (TLC) and 1H-Nuclear Magnetic Resonance Spectroscopy (1H-NMR). A film dispersion method was used to prepare DOX-PA loaded DSPE-PEG micelles. In addition, several methods for characterizing micelle formulations are described, including determination of DOX-PA concentration and encapsulation efficiency, measurement of particle size and distribution, and assessment of in vitro anticancer activities. This protocol provides useful information regarding the preparation and characterization of drug-loaded micelles and thus will facilitate the research and development of novel micelle-based cancer nanomedicines.

show abstract

Issues and concerns in nanotech product development and its commercialization

Cited by 94 publications

References 46 publications

Nanoparticle–allergen complexes for allergen immunotherapy

Nanoparticle–allergen complexes for allergen immunotherapy

Antimicrobial Nanostructures for Neurodegenerative Infections

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Contact Info

Product

Resources

About

Issues and concerns in nanotech product development and its commercialization

Cited by 94 publications

References 46 publications

Nanoparticle&ndash;allergen complexes for allergen immunotherapy

Nanoparticle&ndash;allergen complexes for allergen immunotherapy

Antimicrobial Nanostructures for Neurodegenerative Infections

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Contact Info

Product

Resources

About

Nanoparticle–allergen complexes for allergen immunotherapy

Nanoparticle–allergen complexes for allergen immunotherapy